An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of the National Cancer Institute

• Publication date

  2011-03-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jnci/djr028PMID 21350221PMCID PMC3057983
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

  2012cited by this paper
• NCCN clinical practice guidelines in oncology: prostate cancer early detection.

  2010cited by this paper
• Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Prostate specific antigen best practice statement: 2009 update.

  2009cited by this paper
• Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.

  2009cited by this paper
• Screening and prostate-cancer mortality in a randomized European study.

  2009influential reference
• 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers.

  2009cited by this paper
• Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.

  2009influential reference
• Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

  2009cited by this paper
• Mathematical rigor is necessary, but for men with prostate cancer, clinical relevance is the priority.

  2009cited by this paper
• Outcomes of localized prostate cancer following conservative management.

  2009cited by this paper
• Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program.

  2008cited by this paper
• Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.

  2008cited by this paper
• Is the utility of prostate‐specific antigen velocity for prostate cancer detection affected by age?

  2008cited by this paper
• National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.

  2008cited by this paper
• Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study

  2008cited by this paper
• A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden

  2008cited by this paper
• Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of Curability

  2007influential reference
• Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability.

  2007cited by this paper
• Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

  2006influential reference
• Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower

  2006influential reference
• Radical prostatectomy versus watchful waiting in early prostate cancer.

  2005cited by this paper
• Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

  2005cited by this paper
• Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

  2005influential reference
• Radical prostatectomy versus watchful waiting in early prostate cancer.

  2005cited by this paper
• International assessment of the quality of clinical practice guidelines in oncology using the Appraisal of Guidelines and Research and Evaluation Instrument.

  2004influential reference
• Long-distance mountain biking does not disturb the measurement of total, free or complexed prostate-specific antigen in healthy men

  2004cited by this paper
• Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

  2004cited by this paper
• Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).

  2004cited by this paper
• Implementation of the Prostate Cancer Prevention Trial (PCPT).

  2004influential reference
• Bicycle riding has no important impact on total and free prostate-specific antigen serum levels in older men.

  2003cited by this paper
• Prostate cancer early detection clinical practice guidelines in oncology.

  2003cited by this paper
• The influence of finasteride on the development of prostate cancer.

  2003cited by this paper
• Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing.

  2001cited by this paper
• The influence of ejaculation on serum levels of prostate specific antigen.

  1997cited by this paper
• The effect of bicycle riding on serum prostate specific antigen levels.

  1996cited by this paper
• Ejaculation increases the serum prostate-specific antigen concentration.

  1996cited by this paper
• The impact of ejaculation on serum prostate specific antigen.

  1996cited by this paper
• Effect of ejaculation on prostate-specific antigen levels in normal men.

  1995cited by this paper
• Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

  1994influential reference
• Effect of digital rectal examination (and ejaculation) on serum prostate-specific antigen after twenty-four hours. A randomized, prospective study.

  1993cited by this paper
• Cancer statistics

  1989cited by this paper

• Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia.

  2024cites this paper
• Eight Misconceptions about Prostate-Specific Antigen.

  2024cites this paper
• Prostate cancer biomarkers

  2024cites this paper
• Midlife baseline prostate‐specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality

  2024cites this paper
• Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement.

  2024cites this paper
• Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening

  2023cites this paper
• EARLY DETECTION OF PROSTATE CANCER: AUA/SUO GUIDELINE

  2023cites this paper
• NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ) Prostate Cancer Early Detection Version 1 . 2022 —

  2022cites this paper
• Dottorato di ricerca in TECNOLOGIE AVANZATE IN CHIRURGIA TESI DI DOTTORATO SINGLE SETTING 3D MRI-US GUIDED FROZEN SECTION AND FOCAL CRYOABLATION OF THE INDEX LESION IN LOW/INTERMEDIATE RISK PROSTATE CANCER

  2021cites this paper
• Advancing Traditional Prostate-specific Antigen Kinetics in the Detection of Prostate Cancer: A Machine Learning Model.

  2021cites this paper
• Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology.

  2021cites this paper
• PSA Velocity

  2020cites this paper
• Evaluation of heterogeneous factors of low-grade prostate cancer in patients before and after radical prostatectomy

  2020cites this paper
• Biomarkers in the setting of benign prostatic HyperplasiaInduced lower urinary tract symptoms: What an interventional radiologist needs toKnow.

  2020cites this paper
• Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review

  2020cites this paper
• Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review

  2020cites this paper
• Chapter 2 Biomarkers for Diagnosis and Prognosis of Prostate Cancer

  2019influential citation
• Statistical methods for building better biomarkers of chronic kidney disease

  2019cites this paper
• Potential effect of anti‐inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsy

  2019cites this paper
• Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

  2018cites this paper
• Prostate Cancer Screening: Outcomes and Risk Prediction

  2018cites this paper
• Biomarkers for Diagnosis and Prognosis of Prostate Cancer

  2018influential citation
• Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.

  2018cites this paper
• Identification and evaluation of clinically significant prostate cancer: a step towards personalized diagnosis

  2017cites this paper
• OXGR1 overexpression as putative prostate cancer promoting factor

  2017cites this paper
• Adaptive Linear Contextual Bandits for Online Recommendations

  2017cites this paper
• Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection.

  2017cites this paper
• Screening for prostate cancer.

  2017cites this paper
• What's new in screening in 2015?

  2016cites this paper
• Clarifying the PSA grey zone: The management of patients with a borderline PSA

  2016cites this paper
• Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.

  2016cites this paper
• Dynamic Prediction of Renal Failure Using Longitudinal Biomarkers in a Cohort Study of Chronic Kidney Disease

  2016cites this paper
• Biomarkers in localized prostate cancer.

  2016cites this paper
• An Analytical Study of Prostate-Specific Antigen Dynamics

  2016cites this paper
• Racial and Ethnic Variation in Time to Prostate Biopsy After an Elevated Screening Level of Serum Prostate-specific Antigen.

  2016cites this paper
• The use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

  2016cites this paper
• Prostate-specific Antigen Density Variation Rate as a Potential Guideline Parameter for Second Prostate Cancer Detection Biopsy

  2016cites this paper
• NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ) Prostate Cancer Early Detection

  2016cites this paper
• Prostate Specific Antigen (PSA) growth curves: A method to improve prostate cancer screening

  2015cites this paper
• Evaluating an Elevated Screening PSA Test.

  2015cites this paper
• Gleason 6 Prostate Cancer: Translating Biology into Population Health.

  2015cites this paper
• NCCN Guidelines Version 2 . 2017 Table of Contents Prostate Cancer Early Detection

  2015cites this paper
• Frequentist and Bayesian approaches for a joint model for prostate cancer risk and longitudinal prostate-specific antigen data

  2015cites this paper
• Identification of potential serum and urine biomarkers for patients with prostate cancer using lectin-based proteomic analyses / Jaime Jacqueline Jayapalan

  2015cites this paper
• Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects.

  2015cites this paper
• Advances in Cancer Biomarkers

  2015cites this paper
• The Ethical Dilemma Surrounding Prostate Specific Antigen (PSA) Screening

  2015cites this paper
• The effects of chromosome number changes on mitotic fidelity and karyotype stability

  2015cites this paper
• The use of multiphase non-linear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

  2015cites this paper
• Association between changes in suspicious prostate lesions on serial MRI examinations and follow-up biopsy results.

  2015cites this paper
• Prostate Cancer Early Detection, Version 2.2015

  2015cites this paper
• The many ways to make a luminal cell and a prostate cancer cell.

  2015cites this paper
• Prostate Cancer Early Detection Panel Members

  2015cites this paper
• Novel biomarkers and genomic tests in prostate cancer: a critical analysis.

  2015cites this paper
• Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer.

  2015cites this paper
• [Current role of protatic specific antigen (PSA) and its by-products in the diagnosis of prostate cancer].

  2015cites this paper
• Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.

  2015cites this paper
• Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy.

  2015cites this paper
• Prostate-specific antigen velocity is not better than total prostate-specific antigen in predicting prostate biopsy diagnosis.

  2015influential citation
• Decision analysis of dutasteride use for patients with negative prostate biopsy.

  2015cites this paper
• Prostate Specific Antigen Testing and Prostate Specific Antigen Velocity for the Screening of Prostate Cancer

  2015cites this paper
• Risk stratification of prostate cancer patients based on EPS-urine zinc content.

  2014cites this paper
• Prostate-specific antigen screening in prostate cancer: perspectives on the evidence.

  2014cites this paper
• A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.

  2014cites this paper
• Current clinical application and future prospects

  2014cites this paper
• PSA velocity: a systematic review of clinical applications.

  2014cites this paper
• It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening.

  2014cites this paper
• Prostate specific antigen. Current clinical application and future prospects.

  2014cites this paper
• Kallikreins as Biomarkers for Prostate Cancer

  2014cites this paper
• Impact of PSA levels on second-round screening for the development of prostate cancer in men with low baseline PSA levels (≤2.0 mg/ml).

  2014cites this paper
• Early detection of prostate cancer.

  2014cites this paper
• Prostate cancer: measuring PSA

  2014cites this paper
• Biomarkers in Oncology and Nephrology

  2014cites this paper
• Lipid Genotypes, Phenotypes, and Colorectal Polyps

  2014cites this paper
• Características operativas de la cinética del antígeno prostático específico en el diagnóstico del adenocarcinoma prostático

  2014cites this paper
• MALDI-target integrated platform for affinity-captured protein digestion.

  2014cites this paper
• Evolution and immediate future of US screening guidelines.

  2014cites this paper
• A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer.

  2014cites this paper
• Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer

  2014cites this paper
• van Oort prostate cancer Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic

  2014cites this paper
• Características operativas de la cinética del antígeno prostático específico en el diagnóstico del adenocarcinoma prostáticoOperating characteristics of prostate specific antigen kinetics in the diagnosis of prostate adenocarcinoma

  2014cites this paper
• Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer.

  2013cites this paper
• Patient Perceptions and Shared Decisions About PSA Screening.

  2013cites this paper
• Early detection, PSA screening, and management of overdiagnosis.

  2013cites this paper
• Should follow-up biopsies for men on active surveillance for prostate cancer be restricted to limited templates?

  2013cites this paper
• PSA Velocity in Risk Stratification of Prostate Cancer.

  2013cites this paper
• Changes in serum prostate‐specific antigen levels and the identification of prostate cancer in a large managed care population

  2013cites this paper
• Repeat Prostate Biopsy Strategies: How Many and Where?

  2013cites this paper
• Point: Impact of prostate-specific antigen velocity on management decisions and recommendations.

  2013cites this paper
• SUO CURRICULUM OUTLINE (2013 Update) Topic Author

  2013cites this paper
• Risk stratification in prostate cancer screening

  2013cites this paper
• Prostate cancer: ESMO Consensus Conference Guidelines 2012.

  2013cites this paper
• If something looks too good to be true, it probably is

  2013cites this paper
• Patient Selection and Recommendations on Permanent Seed Implantation as Monotherapy for Localized Prostate Cancer

  2013cites this paper
• The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy

  2013cites this paper
• Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow‐up from a prospective trial

  2013cites this paper
• Screening of Prostate Cancer in Individuals Older than 40 Years of Age with Positive Heredity

  2013cites this paper
• Risk-Based Prostate Cancer Screening: Who and How?

  2013cites this paper